ProGenis Pharmaceuticals is an RNA biotechnology company developing next-generation antisense oligonucleotide (ASO) therapeutics for acquired and inherited rare diseases, including type 2 diabetes. Its precision RNA medicines are designed to regulate disease-causing protein production with low off-target toxicity and broad patient accessibility. The company's platform leverages advanced antisense chemistries and precision manufacturing to create safer, more effective, and affordable treatments for chronic and debilitating conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Many rare and chronic diseases, including specific forms of type 2 diabetes and other acquired or inherited genetic conditions, lack disease-modifying treatment options that precisely target the underlying genetic cause. Existing therapeutic approaches often suffer from off-target toxicity, limited efficacy, and high costs, leaving patients with insufficient care and poor long-term outcomes.
Solution
ProGenis Pharmaceuticals develops next-generation RNA therapeutics using antisense oligonucleotide (ASO) technology to precisely regulate the production of disease-causing proteins. Their ASO drugs are designed to bind to messenger RNA (mRNA) and modulate gene expression, allowing for targeted intervention at the genetic level. The company aims to deliver treatments that are safer, with no or low off-target toxicity, more effective by precisely targeting the gene hallmark, and more accessible through affordable manufacturing and development processes. Their platform integrates advanced antisense chemistries and precision manufacturing capabilities to create breakthrough, disease-modifying therapies for a diverse range of acquired and inherited illnesses.
Target Audience
Primary customers include patients suffering from acquired and inherited rare diseases, as well as healthcare providers, clinical researchers, and pharmaceutical partners seeking disease-modifying RNA therapies. The company also engages with regulatory bodies and investor communities to advance its clinical pipeline.
Features
- Proprietary antisense oligonucleotide (ASO) platform targeting messenger RNA to regulate disease-causing protein production
- Advanced antisense chemistries designed to minimize off-target toxicity and improve safety profiles
- Precision manufacturing capabilities enabling scalable and potentially cost-effective therapeutic development
- Pipeline focused on both acquired and inherited rare diseases, including a type 2 diabetes program supported by MRFF TTRA funding
- Recognition through the 2025 WA Innovators of the Year (Rio Tinto Emerging Innovation Award) for platform innovation